DMI group of institutes in India, Tanzania, Malawi and Zambia to start basic to translational research

August 20, 2025

A MoU for translational research in managing corneal blindnesswas signed among Kanyakumari Medical Mission Research Center (KMMC), Muttom, a nodal institute of DMI foundation in southern most part of India, their associate St. Joseph University in Dar-Es-Salaam, Tanzania, GN Corporation, Japan, their associates NCRM & Medinippon, along with Be Well Hospitals, Chennai, India and Light and Light Ventures, London, UK. In Phases, a Centre of Excellence (CoE) for Regenerative Medicineto translate basic science developments to clinical solutions will be set up in KMMC taking technological guidance from Japanese physician-scientists.

St. Joseph University in Dar-Es-Salaam, Tanzania, DMI St. Eugene University in Lusaka, Zambia, DMI St. John the Baptist University, Mangochi, Malawi to jointly conduct academic and translational research with the CoE in KMMC to develop regenerative medicine solutions for managing locally prevalent healthcare problems.

Please visit below sites for related research papers;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840311

https://doi.org/10.1080/02713683.2023.2180039

07 Apr 2025

The Bees-Haus method (Buccal epithelium Expanded and Encapsulated in Scaffold; Hybrid Approach to Urethral Stricture) of autologous buccal mucosal cell based therapy, earlier reported in India in collaboration with NCRM, has now moved to a clinical application in Japan.

Please visit Businesswire https://businesswire.com/news/home/20250330565540/en/ for more details.

Published in Nature Scientific Reports

01 Mar 2025

neu REFIX® exo-polysaccharide Beta glucan improves Dystrophin in diaphragm, IGF-1 and muscle regeneration markers CD44, MYH3 in Duchenne Muscular Dystrophy model in our research supported by Kochi University, Kyushu University of Medical Sciences and clinicians and scientists in India and Japan.

Please visit https://doi.org/10.1038/s41598-025-92258-4 for details of the study.

Sri Ramachandra Institute team triumphs in the FCQ of NCRM NICHE 2024

02 Dec 2024

Winners of the XIX Fujio Cup Quiz at NCRM NICHE 2024, Zainab Shabbir Rasheed and Saiganesh Venkatesan, posing with the Fujio Cup, joined by Mr. V.R. Venkataachalam, Chancellor, Sri Ramachandra Institute of Higher Education and Research – SRIHER, and Dr. A. Sumathy, Professor and Head, Department of Biomedical Sciences, SRIHER (Left).

A global recognition to our 16-year long research outcome!

30 Nov 2024

In the Genito-Urinary Reconstructive Surgeons (GURS) Masterclass 2024 conducted in United Kingdom, Dr Masayuki Shinchi　and Dr Akio Horiguchi presented the BEES-HAUS autologous cell therapy for male urethral stricture, and were awared the best poster prize.

The basic study started in 2008, through human and animal buccal tissue dervied cells cell culture standardization, pre-clinical and pilot clinical studies now having been recognised in the prestigious international forum, would add further strength to the team in moving forward to make this a routine clinical procedure to imporve the quality of life of patients ailing with urethral stricture.

Please see the link below for more details.

https://www.linkedin.com/feed/update/urn:li:activity:6969439001384558592

Clinical study results of Neu REFIX B-glucans & research updates by Dr. K. Raghavan

06 Oct 2024

Dr. Raghavan, Pediatric Neurologist and first author of the clinical study using Neu REFIX (https://www.sciencedirect.com/science/article/pii/S2667242123000556) gave an update on the ongoing research both clinical and pre-clinical (https://www.nature.com/articles/s41598-023-44330-0) and answered the questions by delegates.

Neu REFIX pre-clinical studies in mdx mice @ AOMC-JMS 2024

05 Oct 2024

Disease modifying approach in managing Duchenne Muscular Dystrophy with Neu REFIX Beta 1,3-1,6 Glucans was presented at the Joint Conference of The 22nd Annual Meeting of Asian and Oceanian Myology Center and The 10th Annual Meeting of Japan Muscle Society; 14, September 2024; Pre-clinical studies using mdx mice yielding reduction in inflammation and fibrosis and decline in fatigue explained; Available to watch in YouTube:

At the MENA Conference on Rare Diseases to be held in Abu Dhabi from May 16, 2024

19 April 2024

Safety and efficacy of our beta-glucan product, “neu REFIX®“, will be presented at the MENA Conference on Rare Diseases to be held in Abu Dhabi from May 16, 2024.

The MENA Rare Diseases Conference brings together experts from various medical fields for presentations, workshops, and group meetings on rare diseases, as well as the latest developments in the diagnosis and treatment of rare diseases and medical and support services for patients. We will be presenting evidence of “Neu-Refix” in Duchenne muscular dystrophy, both in mdx mice pre-clinically and clinically in patients with diagnosis of DMD, BMD and LGMD.

For more information on the conference, please click here.
https://menararediseases.com/

19 April 2024

We will be presenting our unique beta-glucan products, “nichi Glucan®” and “nichi BRITE®“, at the 61st Annual Meeting of the Japanese Society of Surgical Metabolism and Nutrition, which will be held in Osaka from July 25, 2024.

Title: Improvement of intestinal microbiota and neutrophil-lymphocyte ratio (NLR) by nichiglucan and its potential as an adjuvant for pancreatic and liver cancer
Date: Thursday, July 25, 2024　
Venue: Osaka International Convention Center

For more information about the conference, please click here.
https://site.convention.co.jp/jssmn61/guide/